Mycoplasma Coinfection Raises Odds of Severe Pneumonia in Children With hMPV

Human metapneumovirus, a paramyxovirus first identified in 2001, has long been recognized as one of the leading viral causes of lower respiratory tract infection in young children, yet the way the disease presents across different pediatric ages and the factors that push an ordinary infection toward severe pneumonia have remained only partially mapped. A new retrospective study from the Children’s Hospital Affiliated to Shandong University in Jinan, China, now offers one of the most detailed age-stratified pictures to date of hospitalized children with confirmed human metapneumovirus lower respiratory tract infection, and it identifies a familiar bacterial companion, Mycoplasma pneumoniae, as a significant contributor to severe disease in older children. The research, published in Virology Journal, analyzed 1,611 hospitalized children aged from birth to under 18 years between 2023 and 2025, using targeted next-generation sequencing to detect pathogens with high sensitivity.

The scale of the cohort allowed the investigators to divide patients into five age bands and compare clinical, laboratory, radiological, and microbiological features across the full pediatric spectrum, something earlier studies, which often focused narrowly on infants or preschool children, could not do. Among the 1,611 children, 57.4 percent were male, 301 children, or 18.7 percent, developed severe pneumonia, and 36 children, or 2.2 percent, required admission to the intensive care unit. The overall ICU admission rate appears modest, but the distribution across ages was strikingly uneven: infants aged zero to six months had the highest ICU admission rate at 7.9 percent, underscoring that the youngest airways, with their narrow caliber and immature immune responses, remain the most vulnerable to life-threatening hMPV disease.

At the opposite end of the pediatric age range, the picture changed dramatically. Children older than six years showed the highest proportions of atelectasis, at 22.4 percent, unilateral lung involvement, at 65.7 percent, and severe pneumonia, at 31.0 percent. This inversion of the usual risk pattern, in which severity is typically assumed to concentrate in infancy, suggests that school-aged children with human metapneumovirus infection should not be dismissed as low risk. The authors note that the very large radiological associations with severity may partly reflect overlap between imaging findings and the extent-based criteria used to define severe pneumonia, a methodological caveat that tempers but does not eliminate the clinical signal.

To identify which factors were independently associated with severe pneumonia, the team built a multivariable logistic regression model incorporating prespecified clinical, laboratory, and microbiological covariates, with selected laboratory variables analyzed as continuous measures. The results were internally coherent from an immunological standpoint. Atelectasis carried the strongest association, with an adjusted odds ratio of 47.52, followed by underlying chronic disease at 9.49, radiological consolidation at 6.82, fever at 3.29, and wheezing at 2.50. Mycoplasma pneumoniae co-detection nearly doubled the odds of severe pneumonia, with an adjusted odds ratio of 1.90. Higher absolute neutrophil counts, rising 1.47-fold per 5 × 10⁹ per liter, and higher C-reactive protein levels, rising 1.14-fold per 10 mg per liter, both pointed toward the heightened inflammatory activation that accompanies more severe lower airway disease.

Two findings ran in the opposite direction and are among the most intriguing in the study. Higher absolute monocyte counts were associated with lower odds of severe pneumonia, with an adjusted odds ratio of 0.71 per 1 × 10⁹ per liter, and bacterial co-detection as a broad category was also associated with reduced odds, at 0.60. The authors do not overinterpret these inverse associations, but they raise the possibility that a robust monocytic response reflects effective innate immune recruitment, while the broad bacterial co-detection category may be diluted by organisms of uncertain clinical significance detected by the highly sensitive sequencing platform. Targeted next-generation sequencing can identify low-abundance nucleic acids whose pathogenic role is ambiguous, a well-recognized challenge in molecular diagnostics that distinguishes colonization or contamination from true coinfection.

The age gradient of Mycoplasma pneumoniae co-detection was one of the clearest patterns in the entire dataset. Among infants aged zero to six months, only 6.0 percent of hMPV-positive children also tested positive for Mycoplasma pneumoniae, but this proportion climbed steadily with age, reaching 50.0 percent in children older than six years. This trajectory mirrors the known epidemiology of Mycoplasma pneumoniae, which is uncommon in early infancy and peaks in school-aged children and adolescents, likely reflecting cumulative exposure to this slow-growing, cell-wall-deficient bacterium in school and community settings. When human metapneumovirus damages the respiratory epithelium, it may facilitate Mycoplasma adherence and invasion of the lower airway, creating a viral-bacterial synergy that manifests as the higher odds of severe pneumonia observed after multivariable adjustment.

Importantly, the overall age-group term in the primary regression model did not reach statistical significance, meaning that age category per se was not an independent predictor of severity once other clinical and laboratory variables were accounted for. What differed across ages was the constellation of manifestations: young infants presented with the physiological fragility that drives ICU admission, while older children presented with the lobar consolidation, atelectasis, and mycoplasmal coinfection that drive classification as severe pneumonia. This distinction between age as a risk marker and age as a modifier of disease phenotype is a subtle but clinically meaningful contribution of the study, because it implies that clinicians should look for different warning signs at different ages rather than applying a single severity rubric uniformly.

Technically, the study relied on targeted next-generation sequencing of respiratory samples, including nasopharyngeal specimens and bronchoalveolar lavage fluid, to characterize the virome and bacteriome of each patient. Compared with conventional polymerase chain reaction panels, this approach captures a broader range of pathogens without requiring prior suspicion of a specific organism, which is precisely what enabled the systematic assessment of pathogen co-detection that formed a central aim of the work. The retrospective design, single-center setting, and reliance on clinically ordered testing all impose limitations, and the authors appropriately flag the potential circularity between radiological extent findings and the severity definition itself. Nevertheless, the internal consistency of the laboratory markers, with neutrophilia and elevated C-reactive protein tracking severity while monocyte counts inversely associated, lends biological plausibility to the model.

The practical implications for pediatric practice are concrete. For infants under six months with human metapneumovirus lower respiratory tract infection, the high ICU admission rate argues for close monitoring of respiratory status, including work of breathing, oxygen saturation trends, and feeding tolerance, even when the child appears initially stable. For school-aged children, the study suggests peri-admission chest imaging when clinically indicated, given the high frequency of atelectasis and unilateral involvement in this group, and prompt further clinical and microbiological evaluation when Mycoplasma pneumoniae is co-detected, since this combination roughly doubles the odds of severe pneumonia. As surveillance of human metapneumovirus intensifies worldwide, following its recognition as an increasingly appreciated cause of pediatric respiratory hospitalization, studies of this kind provide the age-specific evidence base that clinicians need to triage, investigate, and treat children with this common but heterogeneous infection.

Subject of Research: Age-stratified clinical features and risk factors for severe pneumonia in children hospitalized with human metapneumovirus lower respiratory tract infection

Article Title: Age-stratified clinical features and factors associated with severe pneumonia in hospitalized children with human metapneumovirus–associated lower respiratory tract infection

Article References: Zhang, J., Jiang, Q., Lei, M., Sun, Y., & Ma, X. (2026). Age-stratified clinical features and factors associated with severe pneumonia in hospitalized children with human metapneumovirus–associated lower respiratory tract infection. Virology Journal. https://doi.org/10.1186/s12985-026-03306-y

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03306-y

Keywords: human metapneumovirus, lower respiratory tract infection, severe pneumonia, Mycoplasma pneumoniae, pathogen co-detection, children, next-generation sequencing, atelectasis, C-reactive protein, pediatric intensive care, risk factors, virology